Drug intelligence / Profile preview

LM009

Development stage: Preclinical
Lead developer: Leadermed Group

Overview

LM009 is a preclinical-stage therapeutic candidate being developed by LeaderMed Group, in collaboration with Combiphar, for the treatment of lung fibrosis. As of 2022, the program is in the early stages of development, and specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed by the developers. LeaderMed Group focuses on the development and commercialization of innovative pharmaceutical products for the Asia-Pacific market, often through strategic partnerships and in-licensing agreements.

Beyond the preview

Go deeper on LM009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM009.

Explore the full profile